ADVA
ADVA (FSE: ADV) today announced the latest software release of its core and edge timing technology, bringing new levels of PNT security and resilience to synchronization networks. The upgraded series of PTP grandmaster clock solutions now enables operators to automatically harness public key infrastructure. Along with enhanced certificate management, this delivers more robust security and removes complexity. ADVA’s core and mid-sized PTP grandmaster devices now also integrate enhanced aPNT+™ technology , providing advanced jamming and spoofing detection as well as mitigation with automatic switchover in the event of cyberattacks. The software replaces costly hardware devices previously used for PNT protection and achieves enhanced DHS Level 4 Resiliency in PNT self-survivability, the highest in the industry. What’s more, the new software release supports 100Mbit/s over fiber for interconnectivity with optical timing channels from third-part vendors as well as support for PTP profiles for a wide range of industries.
“Today’s timing networks require greater accuracy than ever before. But mission-critical national networks need improved resilience and security as defined by the latest standards. With our trusted PNT assurance solutions, we’re providing the GNSS protection and cybersecurity that today’s operators need to meet current and future challenges,” said Gil Biran, GM of Oscilloquartz, ADVA. “From phase synchronization in critical national infrastructure to traceable timestamping in financial networks, highly precise and protected timing is key to successful operations. This upgrade sets a new standard for secure synchronization and delivers it to more networks than ever before.”
The new 11.1.1 software release features upgrades to ADVA’s comprehensive range of Oscilloquartz edge timing products, the OSA 5412/22 Series, as well as its core synchronization devices, the OSA 5430/40 Series. The solutions now provide multi-layered security for synchronization infrastructure through improved certification management and PKI. As part of ADVA’s intelligent and scalable assured PNT platform, the ADVA aPNT+™ , the solutions also feature innovation for detection of spoofing and jamming as well as countermeasures to prevent service disruption. With PTP capabilities for new verticals, including the PTP broadcast profiles (SMPTE ST-2059-2/AES67), the new release will bring precise, reliable synchronization to many new customers.
The new release follows the four layers of augmented protection as defined in the DHS Resilient PNT Conformance Framework (IEEE P1952 Resilient PNT UE working group). These are: antenna level with a new anti-jamming antenna; GNSS receiver level with single and multi-band options; device level with state-of-the-art anti-jamming and spoofing technology; and network level with sophisticated anti-jamming and anti-spoofing technology based on our Ensemble Controller with Sync Director management suite. Additionally, the device and network levels integrate multi-source backup for diversity and multi-level fault-tolerant mitigation for trusted PNT assurance protection, prevention and recovery.
“In a lot of industries and government networks, failure of network synchronization is no longer an option. It could have devastating consequences for a business’s future or even put lives at risk. That’s why more and more customers are deploying our portfolio of the most advanced and comprehensive aPNT+™ timing technology. As well as ensuring nanosecond accuracy, our enhanced series of PTP grandmasters now provide the most robust defense against cyberattacks,” commented Nir Laufer, VP of product line management at Oscilloquartz, ADVA. “This release extends many of our most powerful features beyond telecom. It opens the door for government, defense, broadcasters, data centers, smart grids and more to take advantage of technologies like our multi-band receivers and AI-power GNSS protection.”
Further information is available in these slides: https://adva.li/apnt-security-enhancements-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005047/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom